Spectral Domain Optical Coherence Tomography Findings in Patients with Retinitis PigmentosaTriolo G. · Pierro L. · Parodi M.B. · De Benedetto U. · Gagliardi M. · Manitto M.P. · Bandello F.
Department of Ophthalmology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
Keywords: Retinitis pigmentosaPhotoreceptor junctionExternal limiting membraneInner limiting membrane thickening Epiretinal membranesRetinal micropseudocystsCystoid macular edemaMacular holesChoroidal neovascularization
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: To report the morphological macular findings detected by spectral domain optical coherence tomography (SD-OCT) and to determine their prevalence in patients with retinitis pigmentosa (RP). Methods: SD-OCT scans of 176 eyes from 90 patients affected by RP were reviewed. A careful evaluation was carried out on photoreceptor inner/outer segment (IS/OS) junction, external limiting membrane (ELM), inner limiting membrane thickening (ILMT), epiretinal membranes (ERMs), retinal micropseudocysts (MPCs), cystoid macular edema (CME), macular holes (MHs) and choroidal neovascularization (CNV). Results: The photoreceptor IS/OS junction was absent in the foveal region of 24 eyes (13.6%) and disrupted in 84 eyes (47.7%). The ELM was absent in 24 eyes (13.6%), whereas the ILMT was found in 118 eyes (67%). The presence of an ERM was detected in 48 eyes (27.3%). Some sort of vitreomacular alteration (ILMT and/or ERM) was identifiable in a total of 94.3% of eyes with RP. The presence of MPCs was detected in 32 eyes (18.2%). An evident CME was found in 22 eyes (12.5%). We also found MHs in 8 eyes (4.5%) and CNV in 3 eyes (1.7%). Conclusions: Our data indicate that RP is associated with alterations of many retinal layers. In particular, the vitreoretinal interface is affected in 94% of patients, and MPC can be identified in 18% of eyes. SD-OCT may contribute to the understanding of the pathophysiological mechanism involved in RP.
© 2013 S. Karger AG, Basel
- Heckenlively J, Friederich R, Farson C, Pabalis G: Retinitis pigmentosa in the Navajo. Metab Pediatr Ophthalmol 1981;5:201-206.
- Bundey S, Crews SJ: A study of retinitis pigmentosa in the city of Birmingham. I. Prevalence. J Med Genet 1984;21:417-420.
- Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH: Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol 1984;97:357-365.
- Grøndahl J: Estimation of prognosis and prevalence of retinitis pigmentosa and Usher syndrome in Norway. Clin Genet 1987;31:255-264.
- Haim M, Holm NV, Rosenberg T: Prevalence of retinitis pigmentosa and allied disorders in Denmark. I. Main results. Acta Ophthalmol (Copenh) 1992;70:178-186.
- Hartong DT, Berson EL, Dryja TP: Retinitis pigmentosa. Lancet 2006;368:1795-1809.
- Lee SH, Yu HG, Seo JM, Moon SW, Moon JW, Kim SJ, Chung H: Hereditary and clinical features of retinitis pigmentosa in Koreans. J Korean Med Sci 2010;25:918-923.
- Hagiwara A, Yamamoto S, Ogata K, Sugawara T, Hiramatsu A, Shibata M, Mitamura Y: Macular abnormalities in patients with retinitis pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. Acta Ophthalmol 2011;89:122-125.
- Hirakawa H, Iijima H, Gohdo T, Tsukahara S: Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 1999;128:185-191.
- Giusti C, Forte R, Vingolo EM: Clinical pathogenesis of macular holes in patients affected by retinitis pigmentosa. Eur Rev Med Pharmacol Sci 2002;6:45-48.
- Hajali M, Fishman GA, Anderson R: The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 2008;92:1065-1068.
- Grigoropoulos VG, Emfietzoglou J, Nikolaidis P, Chatzistefanou K, Vergados J, Theodossiadis GP, Theodossiadis PG: Optical coherence tomography findings in patients with retinitis pigmentosa and low visual acuity. Ophthalmic Surg Lasers Imaging 2010;41: 35-39.
- Aizawa S, Mitamura Y, Baba T, Hagiwara A, Ogata K, Yamamoto S: Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa. Eye 2009;23:304-308.
- Wakabayashi T, Sawa M, Gomi F, Tsujikawa M: Correlation of fundus autofluorescence with photoreceptor morphology and functional changes in eyes with retinitis pigmentosa. Acta Ophthalmol 2010;88:177-183.
- Sheth SS, Rush RB, Natarajan S: Inner and outer retinal volumetric and morphologic analysis of the macula with spectral domain optical coherence tomography in retinitis pigmentosa. Middle East Afr J Ophthalmol 2012;19:227-230.
- Kim YJ, Joe SG, Lee DH, Lee JY, Kim JG, Yoon YH: Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2013;54:1303-1309.
- Hikichi T, Akiba J, Trempe CL: Prevalence of posterior vitreous detachment in retinitis pigmentosa. Ophthalmic Surg 1995;26:34-38.
- Pruett RC: Retinitis pigmentosa. A biomicroscopical study of vitreous abnormalities. Arch Ophthalmol 1975;93:603-608.
- Pruett RC, Albert DM: Vitreous degeneration in myopia and retinitis pigmentosa. Bull Soc Belge Ophtalmol 1987;223:211-228.
- Vingolo EM, Giusti C, Forte R, Onori P: Vitreal alterations in retinitis pigmentosa: biomicroscopic appearance and statistical evaluation. Ophthalmologica 1996;210:104-107.
- Tremolada G, Pierro L, De Benedetto U, Margari S, Gagliardi M, Maestranzi G, Calori G, Lorenzi M, Lattanzio R: Macular micropseudocysts in early stages of diabetic retinopathy. Retina 2011;31:1352-1358.
- Spalton DJ, Bird AC, Cleary PE: Retinitis pigmentosa and retinal oedema. Br J Ophthalmol 1978;62:174-182.
- Uliss AE, Gregor ZJ, Bird AC: Retinitis pigmentosa and retinal neovascularization. Ophthalmology 1986;93:1599-1603.
- Chang GQ, Hao Y, Wong F: Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron 1993;11:595-605.
- Portera-Cailliau C, Sung CH, Nathans J, Adler R: Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci USA 1994;91:974-978.
- Xu GZ, Li WW, Tso MO: Apoptosis in human retinal degenerations. Trans Am Ophthalmol Soc 1996;94:411-430.
- Lohr HR, Kuntchithapautham K, Sharma AK, Rohrer B: Multiple, parallel cellular suicide mechanisms participate in photoreceptor cell death. Exp Eye Res 2006;83:380-389.
- Rohrer B, Pinto FR, Hulse KE, Lohr HR, Zhang L, Almeida JS: Multidestructive pathways triggered in photoreceptor cell death of the rd mouse as determined through gene expression profiling. J Biol Chem 2004;279:41903-41910.
- Paquet-Durand F, Johnson L, Ekström P: Calpain activity in retinal degeneration. J Neurosci Res 2007;85:693-702.
- Sancho-Pelluz J, Arango-Gonzalez B, Kustermann S, Romero FJ, van Veen T, Zrenner E, Ekström P, Paquet-Durand F: Photoreceptor cell death mechanisms in inherited retinal degeneration. Mol Neurobiol 2008;38:253-269.
- Marano F, Deutman AF, Leys A, Aandekerk AL: Hereditary retinal dystrophies and choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2000;238:760-764.
- Iwakiri R, Okinami S, Hirata A: Two cases of retinitis pigmentosa associated with choroidal neovascularization (in Japanese). Nihon Ganka Gakkai Zasshi 2007;111:606-611.
- Malik A, Sood S, Narang S: Successful treatment of choroidal neovascular membrane in retinitis pigmentosa with intravitreal bevacizumab. Int Ophthalmol 2010;30:425-428.
- Battaglia Parodi M, De Benedetto U, Knutsson KA, Scotti F, Librando A, Bandello F, Iacono P: Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. J Ocul Pharmacol Ther 2012;28:202-204.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.